Aurora and Vertex merger completes July 18 (1"The Pink Sheet" May 7, p. 18)
You may also be interested in...
GlaxoSmithKline/Vertex' Agenerase prodrug will target first-time protease inhibitor patients, a market segment that amprenavir has not penetrated, Vertex VP-Corporate Communications Lynne Brum told analysts during a recent conference call.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials